Drugs / B7-H3.CD28Z.CART
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07390539 | Jul 2026 → Aug 2030 expected | adult medulloblastoma, atypical teratoid rhabdoid tumor, childhood medulloblastoma, embryonal tumor with multilayered rosettes +3 | Robbie Majzner | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07358260 | Jun 2026 → Dec 2029 expected | childhood malignant neoplasm, neuroblastoma | Robbie Majzner | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B7-H3.CD28Z.CART | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07358260 ↗ |
| Known as | B7-H3 CAR T cells | “This cell therapy is called B7- H3.CD28Z.CART, referred to as B7-H3 CAR T cells.” NCT07390539 ↗1“B7-H3.CD28Z.CART / B7-H3 CAR T cells” NCT07358260 ↗ |
| Action | Deplete | “designed to recognize, bind to and help kill cells that express B7-H3.” NCT07358260 ↗ |
| Modality | Cell therapy | “new cell therapy B7-H3.CD28Z.CART / B7-H3 CAR T cells” NCT07358260 ↗ |
| Route | Intravenous | “Modified autologous T cells administered via Intravenous (IV) infusion” NCT07358260 ↗ |